CA2279522C - Biocompatible compounds for pharmaceutical drug delivery systems - Google Patents

Biocompatible compounds for pharmaceutical drug delivery systems Download PDF

Info

Publication number
CA2279522C
CA2279522C CA002279522A CA2279522A CA2279522C CA 2279522 C CA2279522 C CA 2279522C CA 002279522 A CA002279522 A CA 002279522A CA 2279522 A CA2279522 A CA 2279522A CA 2279522 C CA2279522 C CA 2279522C
Authority
CA
Canada
Prior art keywords
formulation
drug
polymer
biocompatible polymer
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002279522A
Other languages
English (en)
French (fr)
Other versions
CA2279522A1 (en
Inventor
James S. Stefely
David W. Schultz
Luke E. Schallinger
Craig A. Perman
Chester L. Leach
Daniel C. Duan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Publication of CA2279522A1 publication Critical patent/CA2279522A1/en
Application granted granted Critical
Publication of CA2279522C publication Critical patent/CA2279522C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CA002279522A 1997-02-07 1998-02-04 Biocompatible compounds for pharmaceutical drug delivery systems Expired - Fee Related CA2279522C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/797,803 1997-02-07
US08/797,803 US6126919A (en) 1997-02-07 1997-02-07 Biocompatible compounds for pharmaceutical drug delivery systems
PCT/US1998/000074 WO1998034596A2 (en) 1997-02-07 1998-02-04 Biocompatible compounds for pharmaceutical drug delivery systems

Publications (2)

Publication Number Publication Date
CA2279522A1 CA2279522A1 (en) 1998-08-13
CA2279522C true CA2279522C (en) 2008-01-15

Family

ID=25171845

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002279522A Expired - Fee Related CA2279522C (en) 1997-02-07 1998-02-04 Biocompatible compounds for pharmaceutical drug delivery systems

Country Status (14)

Country Link
US (3) US6126919A (cg-RX-API-DMAC10.html)
EP (2) EP1815845A3 (cg-RX-API-DMAC10.html)
JP (1) JP2001511179A (cg-RX-API-DMAC10.html)
KR (1) KR100564130B1 (cg-RX-API-DMAC10.html)
CN (1) CN1114400C (cg-RX-API-DMAC10.html)
AT (1) ATE359062T1 (cg-RX-API-DMAC10.html)
AU (1) AU724765B2 (cg-RX-API-DMAC10.html)
CA (1) CA2279522C (cg-RX-API-DMAC10.html)
DE (1) DE69837549T2 (cg-RX-API-DMAC10.html)
HU (1) HUP0001914A3 (cg-RX-API-DMAC10.html)
IL (1) IL130993A0 (cg-RX-API-DMAC10.html)
NZ (1) NZ336903A (cg-RX-API-DMAC10.html)
PL (1) PL196261B1 (cg-RX-API-DMAC10.html)
WO (1) WO1998034596A2 (cg-RX-API-DMAC10.html)

Families Citing this family (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9804001D0 (sv) * 1998-11-23 1998-11-23 Astra Ab New process
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6319521B1 (en) * 1999-02-10 2001-11-20 University Technology Corporation Microparticles of lactide-co-glycolide copolymers and methods of making and using the same
JP4548623B2 (ja) * 1999-02-24 2010-09-22 多木化学株式会社 生体材料
JP2003501375A (ja) * 1999-06-04 2003-01-14 アルザ・コーポレーション 移植可能なゲル組成物および製造方法
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
JP2003516803A (ja) * 1999-12-15 2003-05-20 ズルツァー・オルトペディクス・リミテッド ヒトまたは動物の関節における軟骨欠損または軟骨/骨欠損の修復のための装置
US6651655B1 (en) * 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
EE05167B1 (et) 2000-05-22 2009-06-15 Chiesi Farmaceutici S.P.A. Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele
DE60133203T3 (de) 2000-07-31 2012-02-23 Nycomed Danmark Aps Fentanyl Zusammensetzung für nasale Anwendung
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
CA2417826A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
DE10058829B4 (de) * 2000-11-27 2004-08-26 3M Espe Ag Verwendung von Polysäuren mit enger Molmassenverteilung
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
CA2445516C (en) * 2001-04-26 2007-11-20 New England Pharmaceuticals, Inc. Metered dose delivery device for liquid and powder agents
AR033290A1 (es) 2001-04-30 2003-12-10 Glaxo Group Ltd Derivados antiinflamatorios de androstano
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
ES2222294T3 (es) 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
NZ550304A (en) * 2001-10-26 2008-05-30 Dey L P An antimicrobial preservative-free albuterol inhalation solution for the relief of bronchospasm in children with asthma
CA2470498A1 (en) * 2001-12-21 2003-07-24 3M Innovative Properties Company Medicinal aerosol compositions with an amide and/or ester containing excipient compound
EP1458357B1 (en) * 2001-12-21 2009-03-04 3M Innovative Properties Company Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient
EP1458354A1 (en) * 2001-12-21 2004-09-22 3M Innovative Properties Company Medicinal aerosol formulations comprising ion pair complexes
EP1340503A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Solution aerosol formulation containing esters of 3, 17-dihydroxy oestratriene derivates for pulmonary delivery
ME00077B (me) 2002-03-01 2010-06-10 Chiesi Farm Spa Formoterol najfiniji preparat
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP1531794B1 (en) * 2002-06-28 2017-05-10 Civitas Therapeutics, Inc. Inhalable epinephrine
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
CN1935155A (zh) * 2002-08-27 2007-03-28 寺田弘 治疗药
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
EP2218448B1 (en) 2002-12-13 2015-09-23 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US6931888B2 (en) * 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
KR20050105490A (ko) * 2003-02-26 2005-11-04 오츠카 세이야쿠 가부시키가이샤 경폐 투여용 서방성 제제학적 조성물
US20070155926A1 (en) * 2003-03-28 2007-07-05 Krzysztof Matyjaszewski Degradable polymers
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
FR2854071B1 (fr) * 2003-04-25 2009-01-30 Ethypharm Sa Procede de dispersion de substances hydrosolubles ou hydrophiles dans un fluide a pression supercritique
US7879357B2 (en) * 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
CA2526478A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
WO2005066238A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Medicinal compositions and method for the preparation thereof
US20050271597A1 (en) * 2004-02-13 2005-12-08 Keith Alec D Prostate hypertrophy treatment composition and method
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US7893174B2 (en) 2004-03-05 2011-02-22 Carnegie Mellon University Atom transfer radical polymerization process
US7994225B2 (en) * 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
CA2559208A1 (en) * 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
AU2004322756B2 (en) 2004-08-12 2011-04-14 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
DK2767292T3 (en) 2004-09-17 2016-12-19 Durect Corp RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
US20070286815A1 (en) * 2004-09-24 2007-12-13 Bechtold Kevin J Medicinal Aerosol Formulations and Methods of Synthesizing Ingredients Therefor
AU2006223149A1 (en) * 2005-03-14 2006-09-21 3M Innovative Properties Company Biocompatible polymer compounds for medicinal formulations
JP5749881B2 (ja) 2005-04-22 2015-07-15 ユニヴェルシテ デ ジュネーブ ポリラクチド組成物およびその使用
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US7919583B2 (en) * 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
CN101356197B (zh) 2005-08-23 2016-02-17 卡内基梅隆大学 在微乳液中的原子转移自由基聚合和真实的乳液聚合
WO2007025310A1 (en) 2005-08-26 2007-03-01 Carnegie Mellon University Polymerization process with catalyst reactivation
CA2637569C (en) 2006-01-18 2013-01-08 Yuhua Li Pharmaceutical compositions with enhanced stability
JP2009532339A (ja) * 2006-03-22 2009-09-10 スリーエム イノベイティブ プロパティズ カンパニー 新規製剤
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
US8580307B2 (en) * 2006-06-22 2013-11-12 Ethicon, Inc. High glass transition temperature absorbable microspheres
NZ574533A (en) 2006-08-01 2011-05-27 Glaxo Group Ltd Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
US20080269347A1 (en) * 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
US8367051B2 (en) 2006-10-09 2013-02-05 Carnegie Mellon University Preparation of functional gel particles with a dual crosslink network
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
WO2008148000A1 (en) 2007-05-23 2008-12-04 Carnegie Mellon University Atom transfer dispersion polymerization
US8865797B2 (en) 2007-05-23 2014-10-21 Carnegie Mellon University Hybrid particle composite structures with reduced scattering
WO2008152398A2 (en) * 2007-06-14 2008-12-18 Cipla Limited Formulations for inhalation
US8586007B2 (en) * 2007-10-19 2013-11-19 Wayne State University Co-polymer stabilizers for hydrofluoroalkane dispersions
US9090737B2 (en) * 2007-11-13 2015-07-28 Surmodics, Inc. Viscous terpolymers as drug delivery platform
EP2067471B1 (en) 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
US7979151B2 (en) * 2007-12-06 2011-07-12 International Business Machines Corporation Run-time dispatch system for enhanced product characterization capability
BRPI0820770A2 (pt) * 2007-12-12 2015-06-16 Basf Se Sal solúvel em água polimérico de medicamentos, forma de administração sólida, e, método para produzir sais solúveis em água poliméricos de medicamentos.
DK2291174T3 (en) * 2008-06-03 2015-03-09 Tolmar Therapeutics Inc Liquid compositions comprising biocompatible oligomer-polymer compositions
US8759279B2 (en) * 2008-06-30 2014-06-24 Kimberly-Clark Worldwide, Inc. Fragranced biodegradable film
US8927617B2 (en) 2008-06-30 2015-01-06 Kimberly-Clark Worldwide, Inc. Fragranced water-sensitive film
WO2010008564A2 (en) * 2008-07-16 2010-01-21 Recombinetics Plaice dna transposon system
CN102176911B (zh) 2008-08-11 2014-12-10 葛兰素史密丝克莱恩有限责任公司 新的腺嘌呤衍生物
BRPI0917458A2 (pt) 2008-08-11 2015-12-01 Glaxosmithkline Llc composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US9415197B2 (en) 2008-12-23 2016-08-16 Surmodics, Inc. Implantable suction cup composites and implants comprising same
US8951546B2 (en) 2008-12-23 2015-02-10 Surmodics Pharmaceuticals, Inc. Flexible implantable composites and implants comprising same
US20100168807A1 (en) * 2008-12-23 2010-07-01 Burton Kevin W Bioactive terpolymer compositions and methods of making and using same
US20100158978A1 (en) * 2008-12-23 2010-06-24 Peter Markland Bioactive spray coating compositions and methods of making and uses thereof
US8974808B2 (en) * 2008-12-23 2015-03-10 Surmodics, Inc. Elastic implantable composites and implants comprising same
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
AU2010226604A1 (en) 2009-03-19 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸(siNA)を用いた結合組織増殖因子(CTGF)遺伝子発現のRNA干渉媒介性阻害
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20120010272A1 (en) 2009-03-27 2012-01-12 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411517A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
GB2481561B (en) 2009-03-27 2013-12-11 Univ Carnegie Mellon Preparation of functional star macromolecules
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
BRPI1014854A2 (pt) * 2009-03-30 2016-05-03 Cerulean Pharma Inc "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados"
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
WO2010122088A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
US8399436B2 (en) 2009-04-24 2013-03-19 Glaxo Group Limited N-pyrazolyl carboxamides as CRAC channel inhibitors
MX2012005711A (es) 2009-11-17 2012-10-05 Cipla Ltd Soluciones de inhalacion.
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
US9993441B2 (en) 2009-12-30 2018-06-12 Surmodics, Inc. Controlled release matrix barrier structure for subcutaneous medical devices
RS53745B1 (sr) 2010-02-10 2015-06-30 Glaxosmithkline Llc 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on-maleat
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
WO2012027467A1 (en) 2010-08-26 2012-03-01 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8492512B2 (en) 2010-08-30 2013-07-23 Surmodics Pharmaceuticals, Inc. Process for reducing moisture in a biodegradable implant device
US9113916B2 (en) 2010-08-31 2015-08-25 Zimmer, Inc. Drill bit for osteochondral drilling with guiding element and uses thereof
WO2012052459A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
JP5795643B2 (ja) 2010-10-21 2015-10-14 グラクソ グループ リミテッドGlaxo Group Limited アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
US9644042B2 (en) 2010-12-17 2017-05-09 Carnegie Mellon University Electrochemically mediated atom transfer radical polymerization
AU2012266541A1 (en) 2011-06-08 2014-01-09 Glaxo Group Limited Combination comprising umeclidinium and a corticosteroid
WO2013028756A1 (en) 2011-08-22 2013-02-28 Carnegie Mellon University Atom transfer radical polymerization under biologically compatible conditions
EP2773324A4 (en) * 2011-11-03 2015-07-01 Prec Dermatology Inc STABLE DERMATOLOGICAL AEROSOL FOAMS USING REACTIVE PROPELLERS
US9533297B2 (en) 2012-02-23 2017-01-03 Carnegie Mellon University Ligands designed to provide highly active catalyst complexes
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
EP2928877B1 (en) 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
EP2999337A4 (en) 2013-05-23 2017-03-15 Aztherapies, Inc Methods for delivering cromolyn
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
JP2017505348A (ja) 2014-02-10 2017-02-16 パタラ ファーマ リミテッド ライアビリティ カンパニー 肺疾患治療のための肥満細胞安定剤
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
WO2015143357A2 (en) 2014-03-21 2015-09-24 Boston Scientific Scimed, Inc. Devices and methods for treating a lung
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
ES2917887T3 (es) 2014-11-13 2022-07-12 Glaxosmithkline Biologicals Sa Derivados de adenina que son útiles en el tratamiento de enfermedades alérgicas u otras afecciones inflamatorias
US9982070B2 (en) 2015-01-12 2018-05-29 Carnegie Mellon University Aqueous ATRP in the presence of an activator regenerator
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
GB201516243D0 (en) 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2017085692A1 (en) 2015-11-18 2017-05-26 Glaxosmithkline Intellectual Property (No.2) Limited Pharmaceutical compositions of ribavirin
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingの調節因子としての環状プリンジヌクレオチド
AU2016370779B2 (en) 2015-12-17 2019-07-25 Astex Therapeutics Limited Quinoline-3-carboxamides as H-PGDS inhibitors
CN109475505A (zh) 2016-07-06 2019-03-15 度瑞公司 具有药物组成物、屏障层及药物层的口服剂型
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
JP2019528320A (ja) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh 特発性肺線維症による慢性咳の治療のためのクロモリン組成物
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH CROMOLYN COMPOSITION FOR TREATING LUNG FIBROSIS
WO2018132582A1 (en) 2017-01-12 2018-07-19 Carnegie Mellon University Surfactant assisted formation of a catalyst complex for emulsion atom transfer radical polymerization processes
CN111565711B (zh) 2017-07-20 2023-01-03 阿茨治疗股份有限公司 色甘酸钠和布洛芬的粉末化制剂
JP2021512943A (ja) 2018-01-26 2021-05-20 アピデル エス・アApidel SA 新規なスピロノラクトン製剤およびその使用
MX2020007997A (es) 2018-02-02 2020-12-03 Alexza Pharmaceuticals Inc Dispositivo electrico de aerosol de condensacion.
CA3103920C (en) 2018-06-22 2025-09-16 Ucl Business Ltd COMPOUNDS FOR TREATING DISEASES MEDIATED BY ALPHA-1 ANTITRYPSIN
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
AU2021207583A1 (en) * 2020-01-16 2022-09-01 Kindeva Drug Delivery L.P. Medicinal compositions for carbon dioxide based metered dose inhalers
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
US12612391B2 (en) 2020-12-28 2026-04-28 The General Hospital Corporation Cromolyn derivatives and uses thereof
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2457238A (en) * 1948-12-28 Fractionation of polymeric
US3079299A (en) * 1959-11-16 1963-02-26 Gen Aerosol Corp Self-propelling medicinal ointment composition containing polyethylene and method ofapplication
US3816612A (en) * 1967-03-23 1974-06-11 Degussa Process for the production of basically reacting pharmaceuticals
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3933825A (en) * 1973-05-14 1976-01-20 Bristol-Myers Company Amine salts of acyl lactylic acids
US4011312A (en) * 1975-06-25 1977-03-08 American Home Products Corporation Prolonged release drug form for the treatment of bovine mastitis
US4010196A (en) * 1975-06-25 1977-03-01 American Home Products Corporation Linear polyester salts
US4732763A (en) * 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
CH660488A5 (en) 1982-12-17 1987-04-30 Sandoz Ag (Co)oligomeric hydroxycarboxylic acid derivatives, the preparation thereof, and the use thereof in pharmaceutical compositions
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
US5236702A (en) * 1983-02-28 1993-08-17 Henkel Kommanditgesellschaft Auf Aktien Composition and method for blood coagulation on hard body tissues
US4670250A (en) * 1983-10-21 1987-06-02 Bend Research, Inc. Durable controlled release microcapsules
EP0164817B1 (en) * 1984-03-21 1991-01-23 Imperial Chemical Industries Plc Surfactant
CA1256638A (en) * 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
EP0248051A1 (en) * 1985-11-29 1987-12-09 FISONS plc Pharmaceutical composition including sodium cromoglycate
ATE71520T1 (de) * 1986-03-10 1992-02-15 Burghart Kurt Pharmazeutische zubereitung sowie verfahren zur herstellung derselben.
DE3616020A1 (de) * 1986-05-13 1987-11-19 Opel Adam Ag Verriegelungsmechanismus fuer den handschuhkastendeckel eines fahrzeuges
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
DE3620685A1 (de) * 1986-06-20 1987-12-23 Henkel Kgaa Neue mittel zur abdeckung unverletzter und/oder verletzter bereiche menschlicher oder tierischer haut
ES2053549T3 (es) * 1986-08-11 1994-08-01 Innovata Biomed Ltd Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion.
EP0261572A1 (de) * 1986-09-20 1988-03-30 Boehringer Ingelheim Kg Verfahren zur Herstellung von Lactid
US4851211A (en) * 1986-11-25 1989-07-25 Abbott Laboratories LHRH analog formulations
EP0319555B1 (de) * 1987-05-27 1992-01-29 Kurt Dr. Burghart Transdermal therapeutisch wirkende pharmazeutische zubereitung sowie vorrichtung zum aufbringen der zubereitung
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4981850A (en) * 1988-02-05 1991-01-01 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimido[1,4]azines as bronchodilators
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
DE3825211A1 (de) * 1988-07-25 1990-02-01 Henkel Kgaa Verbesserte koerperresorbierbare knochenwachse (iii)
US5633002A (en) * 1988-10-04 1997-05-27 Boehringer Ingelheim Gmbh Implantable, biodegradable system for releasing active substance
JP2714454B2 (ja) 1988-11-07 1998-02-16 三井東圧化学株式会社 生体吸収性ポリエステルの製造方法
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DE3916020C2 (de) 1989-05-17 1994-06-01 Burkhard Dr Wichert Retardierende Mikropartikel aus bioabbaubaren Polyestern; Verfahren zu deren Herstellung unter Verzicht auf toxische Lösungsmittel und diese Mikropartikel enthaltende pharmazentische Zubereitungen
DE3917617A1 (de) 1989-05-31 1990-12-06 Boehringer Ingelheim Kg Mikronisierte bioabbaubare partikel, verfahren zur ihrer herstellung und ihre verwendung
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
JPH04226125A (ja) 1990-06-23 1992-08-14 Boehringer Ingelheim Kg ポリ−d,l−ラクチドの製造方法及び活性物質の担体としてのそれらの使用
EP0463194A1 (de) 1990-06-23 1992-01-02 Boehringer Ingelheim Kg Verfahren zur Herstellung von Poly-(D,L-lactid) und seine Verwendung als Wirkstoffträger
CA2054909A1 (en) * 1990-12-06 1992-06-07 Maciej Radosz Supercritical mixed-solvent separation of polymer mixtures
SE9100610D0 (sv) * 1991-03-04 1991-03-04 Procordia Ortech Ab Bioresorbable material for medical use
FR2673843B1 (fr) * 1991-03-14 1995-01-13 Centre Nat Rech Scient Composition pharmaceutique implantable, bioresorbable a base de poly(acide lactique), destinee a mettre en óoeuvre une antibiotherapie interne locale.
TW247878B (cg-RX-API-DMAC10.html) * 1991-07-02 1995-05-21 Takeda Pharm Industry Co Ltd
IL103238A (en) * 1991-09-25 1995-07-31 Fisons Plc Pressurised aerosol compositions
US5424063A (en) * 1992-01-09 1995-06-13 The Dow Chemical Company Narrow poly- and mono-dispersed anionic oligomers, and their uses, formulations and process
DK0679088T3 (da) * 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
ES2127835T3 (es) * 1992-10-26 1999-05-01 Sanol Arznei Schwarz Gmbh Procedimiento para la preparacion de microcapsulas.
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
PL174772B1 (pl) 1993-01-06 1998-09-30 Kinerton Ltd Kompozycja farmaceutyczna zawierająca jonowy konjugat cząsteczkowy
DE69405719T2 (de) * 1993-03-17 1998-01-15 Minnesota Mining & Mfg Aerosolzubereitung, enthaltend ein aus einem diol-disäure-derivat abgeleitetes dispergiermittel
KR100321649B1 (ko) * 1993-03-17 2002-07-22 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 에스테르,아미드또는머캅토에스테르로부터유도된분산보조제를함유하는에어로졸제제
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
JP3220331B2 (ja) * 1993-07-20 2001-10-22 エチコン・インコーポレーテツド 非経口投与用の吸収性液体コポリマー類
CA2166469C (en) * 1993-08-13 2002-03-26 Paul Anthony Bowser Cosmetic composition containing hydroxy alkanoate derivatives
US5618911A (en) * 1993-08-19 1997-04-08 Toyo Boseki Kabushiki Kaisha Polymer containing lactic acid as its constituting unit and method for producing the same
JP3339600B2 (ja) 1994-05-23 2002-10-28 東洋紡績株式会社 ポリ乳酸及び/又はその共重合体
JP3367577B2 (ja) 1994-05-24 2003-01-14 東洋紡績株式会社 酸末端封鎖ポリ乳酸
JPH09506097A (ja) * 1993-12-02 1997-06-17 アボツト・ラボラトリーズ 非cfc噴射剤と共に用いるエアロゾル薬物調剤
JP3524195B2 (ja) 1994-02-21 2004-05-10 武田薬品工業株式会社 徐放性製剤用基剤
JP3490171B2 (ja) 1994-02-21 2004-01-26 武田薬品工業株式会社 生体内分解性ポリマーの末端カルボキシル基におけるエステル
ATE178789T1 (de) * 1994-02-21 1999-04-15 Takeda Chemical Industries Ltd Polyester matrix für eine pharmazeutische zusammensetzung mit verzögerter freigabe
WO1996003983A1 (en) * 1994-08-04 1996-02-15 Minnesota Mining And Manufacturing Company Inhibition of leukotriene biosynthesis with urea derivatives
US5478921A (en) * 1994-08-25 1995-12-26 United States Surgical Corporation Method of purifying bioabsorable polymer
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
EP0727711A3 (en) * 1995-02-17 1997-04-09 Ocg Microelectronic Materials Photoresist compositions containing supercritical fluid fractionated polymeric resin binders
US5618850A (en) * 1995-03-09 1997-04-08 Focal, Inc. Hydroxy-acid cosmetics
US5633022A (en) 1995-06-08 1997-05-27 Old Line Plastics, Inc. Differential temperature vacuum-forming tool
JPH0959218A (ja) 1995-08-25 1997-03-04 Shimadzu Corp L−乳酸オリゴマー誘導体
JPH09124778A (ja) 1995-10-31 1997-05-13 Shimadzu Corp ポリ乳酸の製造法
IL126422A (en) * 1996-04-23 2004-02-19 Kinerton Ltd Biodegradable acidic polylactic polymers and methods for their preparation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems

Also Published As

Publication number Publication date
WO1998034596A2 (en) 1998-08-13
PL335020A1 (en) 2000-03-27
JP2001511179A (ja) 2001-08-07
HUP0001914A3 (en) 2001-12-28
IL130993A0 (en) 2001-01-28
ATE359062T1 (de) 2007-05-15
HUP0001914A2 (hu) 2000-10-28
DE69837549T2 (de) 2007-12-20
WO1998034596A3 (en) 1998-11-05
US20020164290A1 (en) 2002-11-07
EP1014944A2 (en) 2000-07-05
EP1014944B1 (en) 2007-04-11
NZ336903A (en) 2001-08-31
US6416742B1 (en) 2002-07-09
KR20000070863A (ko) 2000-11-25
EP1815845A3 (en) 2008-08-06
US6126919A (en) 2000-10-03
PL196261B1 (pl) 2007-12-31
AU6238498A (en) 1998-08-26
DE69837549D1 (de) 2007-05-24
CN1246790A (zh) 2000-03-08
EP1815845A2 (en) 2007-08-08
KR100564130B1 (ko) 2006-03-27
CA2279522A1 (en) 1998-08-13
HK1030357A1 (en) 2001-05-04
CN1114400C (zh) 2003-07-16
AU724765B2 (en) 2000-09-28
US7687054B2 (en) 2010-03-30

Similar Documents

Publication Publication Date Title
US7687054B2 (en) Biocompatible compounds for sustained release pharmaceutical drug delivery systems
CA2156408C (en) Aerosol formulation containing a polyester dispersing aid
US20080112894A1 (en) Biocompatible Polymer Compounds For Medicinal Formulations
AU761559B2 (en) Biocompatible compounds for pharmaceutical drug delivery systems
AU2003204078B2 (en) Biocompatible compounds for pharmaceutical drug delivery systems
HK1108365A (en) Biocompatible compounds for pharmaceutical drug delivery systems
HK1030357B (en) Biocompatible compounds for pharmaceutical drug delivery systems
MXPA99007322A (es) Compuestos biocompatibles para sistemas de administracion de medicamentos farmaceuticos
CZ277299A3 (cs) Biokompatibilní sloučeniny pro farmaceutické podávači systémy léčiv
JP2007517032A (ja) 医薬組成物およびこれらの調製方法

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130204